<span item_type="fundamental" item_id="0ded8fd5422233277e5f9584b573c9fc" counter_id="ST/US/ASPCR" env="prod"></span><span item_type="announcement" item_id="549085906994076801" env="prod"></span><p>EPS: As of FY2025 Q2, the actual value is USD 0.11.</p><p></p><h3>Segment Revenue</h3><ul><li>The company has not generated any operating revenues as of June 30, 2025, and expects to generate non-operating income in the form of interest income on marketable securities held in the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li></ul><h3>Operational Metrics</h3><ul><li>For the three months ended June 30, 2025, the company reported a net income of $379,939, primarily due to interest income of $646,975, offset by general and administrative expenses of $267,036.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li><li>For the six months ended June 30, 2025, the company reported a net income of $793,141, with interest income of $1,294,055 and general and administrative expenses of $500,914.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li></ul><h3>Cash Flow</h3><ul><li>Net cash used in operating activities for the six months ended June 30, 2025, was - $254,160, primarily due to interest earned on marketable securities held in the Trust Account.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li><li>Net cash used in financing activities for the same period was - $276,221, related to the repayment of a promissory note to a related party.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li></ul><h3>Unique Metrics</h3><ul><li>The company has $61,624,847 in investments held in the Trust Account as of June 30, 2025, which are comprised of money market funds that invest in U.S. government securities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><ul><li><strong>Core Business Focus</strong>: The company is focused on completing a Business Combination within 12 months from the closing of the IPO, with the possibility of extending this period to 18 months. The company has entered into a merger agreement with Bioserica International Limited, with an aggregate consideration of $217,860,000, payable in newly issued shares.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li><li><strong>Non-Core Business</strong>: The company terminated a previous agreement with HD Group and is now pursuing the merger with Bioserica, reflecting a strategic shift towards the bio-based antimicrobial materials sector.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1890361/000121390025075713/ea0252005-10q_aspac3.htm"></span></li></ul>

A SPAC III ACQUISITION CORP. COM NPV CL A (SUBS/RTS) 02/01/2026 | 10-Q: FY2025 Q2 EPS: USD 0.11